Termination of Material Agreement (Form 8-K)

Item 1.02 Termination of a Material Definitive Agreement.

Effective September 19, 2025, Lexaria Bioscience Corp. (the "Company") terminated the Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC (the "Agent"), as originally entered into on August 21, 2024 (the full text having been filed as Exhibit 1.1 to the Company's Current Report on Form 8-K filed August 22, 2024) and, as amended by Amendment No. 1 on February 5, 2025 (the full text having been filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed February 5, 2025) collectively the "Sales Agreement". The Sales Agreement provided that the Company may issue and sell, from time to time, up to $5,000,000 in aggregate principal amount of shares (the "Shares") of the Company's common stock through or to the Agent, as the Company's sales agent or principal. As at the date of termination, the Company had sold an aggregate 14,995 Shares under the Sales Agreement for gross proceeds of $38,236.00.